Bioactivity | FPR2 agonist 2 is a potent and permeates the blood−brain barrier FPR2 agonist with an EC50 of 0.13 µM, 1.1 µM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity[1]. |
Target | EC50: 0.13 µM (FPR2); 1.1 µM (FPR1) |
Invitro | FPR2 agonist 2 (compound (S)-11l) (1-100 µM; 48 h) exhibits low cytotoxicity with an EC50 value of 20.8 µM in N9 cells[1].FPR2 agonist 2 (FPR1/FPR2 HL60 cells) shows agonist activity with EC50s of 0.13 µM, 1.1 µM (IC50s of 0.085 µM, Not determined) for FPR2 and FPR1, respectively[1].FPR2 agonist 2 (0.1 µM) effectively blocks LPS-induced cell death and NO production and effectively suppresses the effect of LPS stimulation[1].FPR2 agonist 2 (0.1 µM) counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity[1]. Cell Viability Assay[1] Cell Line: |
In Vivo | FPR2 agonist 2 (1 mg/kg for i.v.; 10 mg/kg for i.p.) shows the ability to permeate the blood−brain barrier and to accumulate in the brain[1]. Animal Model: |
Name | FPR2 agonist 2 |
CAS | 2829263-20-7 |
Formula | C25H20F2N4O2 |
Molar Mass | 446.45 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Mastromarino M, et al. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders. J Med Chem. 2022; 65(6):5004-5028. |